Clinical Trials Browser

Recruiting × Triple Negative Breast Neoplasms × neratinib × Clear all

NCT01042379 2026-03-13

I-SPY

Phase 2 Recruiting

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT06008275 2025-11-10

Neratinib in Combination With Ruxolitinib in Patients With mTNBC

Phase EARLY_PHASE1 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms